Effects of drospirenone on cardiovascular markers in human aortic endothelial cells

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–33
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–12
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004; 217: 255–61
   PubMed Web of Science ®Google Scholar
• Khaw K T. Epidemiology of coronary heart disease in women. Heart 2006; 92: 2–4
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419–20
   PubMed Web of Science ®Google Scholar
• van Baal W M, Kenemans P, Emeis J J, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71: 663–70
   PubMed Web of Science ®Google Scholar
• Scarabin P Y, Alhenc-Gelas M, Oger E, Plu-Bureau G. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women–a randomised controlled trial. Thromb Haemost 1999; 81: 673–5
   PubMed Web of Science ®Google Scholar
• Van Baal W M, Emeis J J, Kenemans P, et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999; 29: 913–21
   PubMed Web of Science ®Google Scholar
• Stork S, von Schacky C, Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 2002; 165: 301–7
   PubMed Web of Science ®Google Scholar
• Seljeflot I, Arnesen H, Hofstad A E, Os I. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemost 2000; 83: 944–8
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Kroupis C, Kyriakides Z S, Koniavitou K, Kremastinos D T. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease. Eur Heart J 2000; 21: 975–80
   PubMed Web of Science ®Google Scholar
• Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717–22
   PubMed Web of Science ®Google Scholar
• Koh K K, Son J W, Ahn J Y, et al. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int J Cardiol 2001; 81: 43–50
   PubMed Web of Science ®Google Scholar
• Stork S, Baumann K, von Schacky C, Angerer P. The effect of 17beta-estradiol on MCP-1 serum levels in postmenopausal women. Cardiovasc Res 2002; 53: 642–9
   PubMed Web of Science ®Google Scholar
• Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. J Cardiol 2005; 96: 148–53
   Web of Science ®Google Scholar
• Kohler H P, Grant P J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792–801
   PubMed Web of Science ®Google Scholar
• Sobel M I, Winkel C A, Macy L B, Liao P, Bjornsson T D. The regulation of plasminogen activators and plasminogen activator inhibitor type 1 in endothelial cells by sex hormones. Am J Obstet Gynecol 1995; 173: 801–8
   PubMed Web of Science ®Google Scholar
• Mueck A O, Seeger H, Wallwiener D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 2002; 9: 273–81
   PubMed Web of Science ®Google Scholar
• Kroon U B, Tengborn L, Rita H, Backstrom A C. The effect of transdermal oestradiol and oral progestogens on haemostasis variables. Br J Obstet Gynaecol 1997; 104: 32–37
   PubMedGoogle Scholar
• Scarabin P Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071–8
   PubMed Web of Science ®Google Scholar
• Koh K K, Jin D K, Yang S H, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001; 103: 1961–6
   PubMed Web of Science ®Google Scholar
• Teede H J, McGrath B P, Smolich J J, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404–9
   PubMed Web of Science ®Google Scholar
• Lobo R A, Bush T, Carr B R, Pickar J H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13–24
   PubMed Web of Science ®Google Scholar
• Schlegel W, Petersdorf L I, Junker R, Schulte H, Ebert C, von Eckardstein A. The effects of six months treatment with a low-dose of conjugated oestrogens in menopausal women. Clin Endocrinol 1999; 51: 643–51
   PubMed Web of Science ®Google Scholar
• Karara A H, Hanes V, Alonso A, et al. Pharmacokinetics and pharmacodynamics of drospirenone–estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. J Clin Pharmacol 2007; 47: 1292–302
   PubMed Web of Science ®Google Scholar